Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Humana Inc. ($HUM) is the largest pure-play Medicare Advantage health maintenance organization in the United States, established as a new fund position during the quarter. The investment manager adopts a strongly bullish posture, framing the stock as an asymmetric turnaround opportunity where trough 2026 earnings dramatically understate the normalized earnings capacity of the franchise. From a financial mechanics perspective, Humana's current near-breakeven operating margin reflects an actuarial pricing lag and transient CMS Star Rating bonus downgrades rather than permanent structural impairment. As adjusted EPS compressed from $17.14 in 2025 to roughly $9.00 in 2026, the stock de-rated to single-digit multiples of its normalized earnings power. Humana's turnaround pathway relies on disciplined contract repricing, exiting unprofitable counties, and recovering top-quartile Star Ratings, which would unlock substantial revenue quality bonuses and drive pre-tax margins back toward target 3% levels. Key catalysts to monitor include finalized CMS reimbursement adjustments - such as the 2.48% rate increase approved for 2027 - annual Star Rating restoration for the 2028 bonus cycle, and management's roadmap to deliver $36 to $44 in EPS by 2028. Primary risks comprise continued cost utilization spikes in senior patient care, administrative friction in Medicare Advantage rate-setting, and operational execution errors in benefit repricing.” | BULL | Q3 2026 Oct 14, 2026 | View Pitch |
Eagle Capital Management Ravenel B. Curry III | “Humana has significant scale advantages in a consolidated industry that outgrows the overall economy. The industry moves with its own cycle and, over the last several years, has faced cost/price pressures in Medicare Advantage and Medicaid. Some weaker firms are unprofitable. We believe conditions have bottomed out and that we are transitioning to a multi-year improvement in margins and earnings. Humana is making good strides, and we expect significantly improved Star ratings for the company later this year.” | NEUTRAL | Q2 2026 Aug 4, 2026 | View Pitch |
Diamond Hill Large Cap Strategy Austin Hawley | “Health care services and insurance company Humana is a new holding in 2Q26 and the second-largest Medicare Advantage insurer in the US. Shares outperformed in 2Q26 after the company delivered strong 1Q26 results and on better-than-expected Medicare rate increases announced in early April, which will be helpful for the industry in closing the gap between pricing and cost trends. Health care services and insurance company Humana is the second-largest Medicare Advantage insurer in the US. Margins have been squeezed in recent years from rising medical costs and lower government reimbursement; however, we believe margins will normalize upward over time as the company prices to reflect higher utilization and as government reimbursement rates improve. Relative to a more normal earnings base, we believe the valuation is very attractive.” | BULL | Q2 2026 Jul 17, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.